Mednet Logo
HomeRadiation OncologyQuestion

How does Decipher score inform your practice for treating pelvic nodes in otherwise favorable intermediate risk prostate cancer?

3
5 Answers
Mednet Member
Mednet Member
Radiation Oncology · University of New Mexico School of Medicine

Nodal radiation therapy in prostate cancer remains controversial. While the Decipher score correlates with lymph node involvement in pathological specimens, I have not used it to decide on pelvic nodal radiation. Two randomized studies failed to show a benefit to pelvic radiation (old studies with i...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Lafayette Radiation Center

There is data showing decipher is predictive for PSMA positive nodes. For UFIR, if high decipher, I consider nodal RT.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Marshfield Clinic - Rice Lake

It's not unreasonable to use any valid predictor in decision making. I use the Partin tables and MSK nomograms as a predictor of lymph node involvement, and if the rate is less than 10%, don't treat the nodes, and if it's 10%+, consider it. A very high decipher score indicates an increased risk of m...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

I would be hard pressed based on current evidence to consider adding LNRT to an FIR patient because of a Decipher score.

I personally go by MSKCC nomogram with a threshold of 15% and have, to date, not met an FIR patient who would meet the criteria. Some UIR patients can meet those criteria without ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Jacob E Locke MD PA

UIR with PSA<10 and a negative PSMA PET (other than prostate) with high decipher.. time to put this up on a slide and let the crowd vote....

Register or Sign In to see full answer

How does Decipher score inform your practice for treating pelvic nodes in otherwise favorable intermediate risk prostate cancer? | Mednet